HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
$158.83M
Mr. Jorn Aldag
131.00
New York, NY
Apr 18, 2019
-1.15
$-4.12
2.77
3.86
-93.16%
-1.23
-0.06
0.70
3.08
3.86
-38.86%
-51.77%
Similar stocks (8)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Eledon Pharmaceuticals, Inc.
ELDN
ETF Exposure (8)
Dimensional U.S. Core Equity 2 ETF
DFAC
4.8101e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.3622999999999998e-4%
Dimensional U.S. Targeted Value ETF
DFAT
1.5322e-4%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (8)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Eledon Pharmaceuticals, Inc.
ELDN
ETF Exposure (8)
Dimensional U.S. Core Equity 2 ETF
DFAC
4.8101e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.3622999999999998e-4%
Dimensional U.S. Targeted Value ETF
DFAT
1.5322e-4%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%